Strong Q3 Performance: Sequential Revenue Growth of 0.6% in CC, Large Deal Wins of $4.8 billion
Revenue Guidance for FY 26 revised to 3.0%-3.5%BENGALURU, India, Jan. 14, 2026…
Online Casino Real Money No Deposit Bonus Get $5 No Deposit Bonus + Large Welcome Bonus By BC Poker
New York City, NY, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Players searching…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
July 29, 2025 09:01 ET | Source: Windtree Therapeutics Investors choose to…
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial…
